Cited by 194DNA Repair MechanismsCancer therapeutics and mechanismsPARP inhibition in cancer therapy

The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.

A Small Molecule Targeting Mutagenic Translesion Synthesis Improves Chemotherapy

Open access

Wojtaszek, Jessica L., Chatterjee, Nimrat, Najeeb, Javaria, Ramos, Azucena, Lee, Minhee, Bian, Ke, Xue, Jenny Y., Fenton, Benjamin A., Park, Hyeri, Li, Deyu, Hemann, Michael T., Hong, Jiyong, Walker, Graham C., Zhou, Pei·2019·Cell

DOI 10.1016/j.cell.2019.05.028PMC PMC6644000

Open this paper in CoChat — free account Open PDF

Abstract

Intrinsic and acquired drug resistance and induction of secondary malignancies limit successful chemotherapy. Because mutagenic translesion synthesis (TLS) contributes to chemoresistance as well as treatment-induced mutations, targeting TLS is an attractive avenue for improving chemotherapeutics. However, development of small molecules with high specificity and in vivo efficacy for mutagenic TLS has been challenging. Here, we report the discovery of a small-molecule inhibitor, JH-RE-06, that disrupts mutagenic TLS by preventing recruitment of mutagenic POL ζ. Remarkably, JH-RE-06 targets a nearly featureless surface of REV1 that interacts with the REV7 subunit of POL ζ. Binding of JH-RE-06 induces REV1 dimerization, which blocks the REV1-REV7 interaction and POL ζ recruitment. JH-RE-06 inhibits mutagenic TLS and enhances cisplatin-induced toxicity in cultured human and mouse cell lines. Co-administration of JH-RE-06 with cisplatin suppresses the growth of xenograft human melanomas in mice, establishing a framework for developing TLS inhibitors as a novel class of chemotherapy adjuvants.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.cell.2019.05.028

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Coot : model-building tools for molecular graphics
Emsley, P., & Cowtan, K. (2004) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444904019158 · Cited by 30,571
XDS
Kabsch, W. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909047337 · Cited by 16,463
PHENIX : building new software for automated crystallographic structure determination
Adams, P. D., Grosse-Kunstleve, R. W., Hung, L.-W., Ioerger, T. R., McCoy, A. J., Moriarty, N. W., Read, R. J., Sacchettini, J. C., Sauter, N. K., & Terwilliger, T. C. (2002) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444902016657 · Cited by 4,361
REV7 counteracts DNA double-strand break resection and affects PARP inhibition
Xu, G., Chapman, J. R., Brandsma, I., Yuan, J., Mistrík, M., Bouwman, P., Bártková, J., Gogola, E., Warmerdam, D. O., Barazas, M., et al. (2015) · Nature · doi:10.1038/nature14328 · Cited by 611
Estimation of rat mammary tumor volume using caliper and ultrasonography measurements
Faustino‐Rocha, A. I., Oliveira, P. A., Pinho, J. O., Teixeira-Guedes, C., Soares, R. M. M., da Costa, R. M. G., Colaço, B., Pires, M. J., Colaço, J., Ferreira, R. M., et al. (2013) · Lab Animal · doi:10.1038/laban.254 · Cited by 504
Enhancing tumor cell response to chemotherapy through nanoparticle-mediated codelivery of siRNA and cisplatin prodrug
Xu, X., Xie, K., Zhang, X.-Q., Pridgen, E. M., Park, G. Y., Cui, D. S., Shi, J., Wu, J., Kantoff, P. W., Lippard, S. J., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1303958110 · Cited by 340
Self-citation
MAD2L2 controls DNA repair at telomeres and DNA breaks by inhibiting 5′ end resection
Boersma, V., Moatti, N., Segura‐Bayona, S., Peuscher, M. H., van der Torre, J., Wevers, B. A., Orthwein, A., Durocher, D., & Jacobs, J. J. L. (2015) · Nature · doi:10.1038/nature14216 · Cited by 311
Two-polymerase mechanisms dictate error-free and error-prone translesion DNA synthesis in mammals
Shachar, S., Ziv, O., Avkin, S., Adar, S., Wittschieben, J., Reißner, T., Chaney, S., Friedberg, E. C., Wang, Z., Carell, T., et al. (2009) · The EMBO Journal · doi:10.1038/emboj.2008.281 · Cited by 284
Translesion DNA polymerases in eukaryotes: what makes them tick?
Vaisman, A., & Woodgate, R. (2017) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.1080/10409238.2017.1291576 · Cited by 261
Translesion and Repair DNA Polymerases: Diverse Structure and Mechanism
Yang, W., & Gao, Y. (2018) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-062917-012405 · Cited by 245

Flagged first, then by citations

Show all 39 references

Sorted by citations

Mechanisms of Multidrug Resistance in Cancer Chemotherapy
Bukowski, K., Kciuk, M., & Kontek, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093233 · Cited by 1,853
The rediscovery of platinum-based cancer therapy
Rottenberg, S., Disler, C., & Perego, P. (2020) · Nature reviews. Cancer · doi:10.1038/s41568-020-00308-y · Cited by 993
Cancer drug-tolerant persister cells: from biological questions to clinical opportunities
Russo, M., Chen, M., Mariella, E., Peng, H., Rehman, S. K., Sancho, E., Sogari, A., Toh, T. S., Balaban, N. Q., Batlle, E., et al. (2024) · Nature Reviews Cancer · doi:10.1038/s41568-024-00737-z · Cited by 210
Chasing molecular glue degraders: screening approaches
Domostegui, A., Nieto-Barrado, L., Perez-Lopez, C., & Mayor-Ruiz, C. (2022) · Chemical Society Reviews · doi:10.1039/d2cs00197g · Cited by 200
Temporally distinct post-replicative repair mechanisms fill PRIMPOL-dependent ssDNA gaps in human cells
Tirman, S., Quinet, A., Wood, M. D., Meroni, A., Cybulla, E., Jackson, J., Pegoraro, S., Simoneau, A., Zou, L., & Vindigni, A. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.09.013 · Cited by 202
Molecular glues for protein-protein interactions: Progressing toward a new dream
Konstantinidou, M., & Arkin, M. R. (2024) · Cell chemical biology · doi:10.1016/j.chembiol.2024.04.002 · Cited by 200
REV1-Polζ maintains the viability of homologous recombination-deficient cancer cells through mutagenic repair of PRIMPOL-dependent ssDNA gaps
Taglialatela, A., Leuzzi, G., Sannino, V., Cuella-Martin, R., Huang, J., Wu-Baer, F., Baer, R. J., Costanzo, V., & Ciccia, A. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.08.016 · Cited by 183
PARP inhibition impedes the maturation of nascent DNA strands during DNA replication
Vaitsiankova, A., Burdová, K., Sobol, M. A., Gautam, A., Benada, O., Hanzlíková, H., & Caldecott, K. W. (2022) · Nature Structural & Molecular Biology · doi:10.1038/s41594-022-00747-1 · Cited by 172
Leveraging the replication stress response to optimize cancer therapy
Cybulla, E., & Vindigni, A. (2022) · Nature reviews. Cancer · doi:10.1038/s41568-022-00518-6 · Cited by 144
Defining molecular glues with a dual-nanobody cannabidiol sensor
Cao, S., Kang, S., Mao, H., Yao, J., Gu, L., & Zheng, N. (2022) · Nature Communications · doi:10.1038/s41467-022-28507-1 · Cited by 125
Inhibition of the translesion synthesis polymerase REV1 exploits replication gaps as a cancer vulnerability
Nayak, S. U., Calvo, J. A., Cong, K., Peng, M., Berthiaume, E. A., Jackson, J., Zaino, A. M., Vindigni, A., Hadden, M. K., & Cantor, S. B. (2020) · Science Advances · doi:10.1126/sciadv.aaz7808 · Cited by 119
CDK-Independent and PCNA-Dependent Functions of p21 in DNA Replication
Mansilla, S. F., De La Vega, M. B., Calzetta, N. L., Siri, S. O., & Gottifredi, V. (2020) · Genes · doi:10.3390/genes11060593 · Cited by 114
Molecular glues and bifunctional compounds: Therapeutic modalities based on induced proximity
Schreiber, S. L. (2024) · Cell Chemical Biology · doi:10.1016/j.chembiol.2024.05.004 · Cited by 112
DNA polymerase ζ in DNA replication and repair
Martin, S. K., & Wood, R. D. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz705 · Cited by 119
Exploiting replication gaps for cancer therapy
Cong, K., & Cantor, S. B. (2022) · Molecular Cell · doi:10.1016/j.molcel.2022.04.023 · Cited by 107
POLθ processes ssDNA gaps and promotes replication fork progression in BRCA1-deficient cells
Schrempf, A., Bernardo, S., Arasa-Verge, E. A., Ramírez-Otero, M. A., Wilson, J., Kirchhofer, D., Timelthaler, G., Ambros, A. M., Kaya, A., Wieder, M., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111716 · Cited by 92
Tertiary lymphoid structures are critical for cancer prognosis and therapeutic response
Zhang, Q., & Wu, S. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1063711 · Cited by 86
HMCES Maintains Replication Fork Progression and Prevents Double-Strand Breaks in Response to APOBEC Deamination and Abasic Site Formation
Mehta, K. P. M., Lovejoy, C. A., Zhao, R., Heintzman, D. R., & Cortez, D. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107705 · Cited by 75
Roles of trans-lesion synthesis (TLS) DNA polymerases in tumorigenesis and cancer therapy
Anand, J. R., Chiou, L. F., Sciandra, C. A., Zhang, X., Hong, J., Wu, D., Zhou, P., & Vaziri, C. (2023) · NAR Cancer · doi:10.1093/narcan/zcad005 · Cited by 75
Self-citation
PrimPol‐mediated repriming facilitates replication traverse of DNA interstrand crosslinks
González‐Acosta, D., Blanco‐Romero, E., Ubieto‐Capella, P., Mutreja, K., Miguez-Amil, S., Llanos, S., Garcı́a, F., Muñoz, J., Blanco, L., Lopes, M., et al. (2021) · The EMBO Journal · doi:10.15252/embj.2020106355 · Cited by 73
A modified fluctuation-test framework characterizes the population dynamics and mutation rate of colorectal cancer persister cells
Russo, M., Pompei, S., Sogari, A., Corigliano, M., Crisafulli, G., Puliafito, A., Lamba, S., Erriquez, J., Bertotti, A., Gherardi, M., et al. (2022) · Nature Genetics · doi:10.1038/s41588-022-01105-z · Cited by 71
Structure and mechanism of B-family DNA polymerase ζ specialized for translesion DNA synthesis
Malik, R., Kopylov, M., Gómez-Llorente, Y., Jain, R., Johnson, R. E., Prakash, L., Prakash, S., Ubarretxena‐Belandia, I., & Aggarwal, A. K. (2020) · Nature Structural & Molecular Biology · doi:10.1038/s41594-020-0476-7 · Cited by 67
Comprehensive interrogation of synthetic lethality in the DNA damage response
Fielden, J., Siegner, S. M., Gallagher, D. N., Schröder, M., Stritto, M. R. D., Lam, S., Kobel, L., Schlapansky, M. F., Jackson, S. P., Ćejka, P., et al. (2025) · Nature · doi:10.1038/s41586-025-08815-4 · Cited by 66
Molecular glues modulate protein functions by inducing protein aggregation: A promising therapeutic strategy of small molecules for disease treatment
Wu, H., Yao, H., He, C., Jia, Y., Zhu, Z., Xu, S., Li, D., & Xu, J. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.03.019 · Cited by 63
Self-citation
Molecular basis for assembly of the shieldin complex and its implications for NHEJ
Liang, L., Feng, J., Zuo, P., Yang, J., Lu, Y., & Yin, Y. (2020) · Nature Communications · doi:10.1038/s41467-020-15879-5 · Cited by 56
Mitotic syndicates Aurora Kinase B (AURKB) and mitotic arrest deficient 2 like 2 (MAD2L2) in cohorts of DNA damage response (DDR) and tumorigenesis
Marima, R. M., Hull, R., Penny, C. B., & Dlamini, Z. (2021) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2021.108376 · Cited by 55
REV1 inhibitor JH-RE-06 enhances tumor cell response to chemotherapy by triggering senescence hallmarks
Chatterjee, N., Whitman, M. A., Harris, C. A., Min, S. M., Jonas, O. H., Lien, E. C., Luengo, A., Heiden, M. G. V., Hong, J., Zhou, P., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2016064117 · Cited by 55
Self-citation
Tyrosine catabolism enhances genotoxic chemotherapy by suppressing translesion DNA synthesis in epithelial ovarian cancer
Li, J., Zheng, C., Mai, Q., Huang, X., Pan, W., Lu, J., Chen, Z., Zhang, S., Zhang, C., Huang, H., et al. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.10.002 · Cited by 48
Specialized replication mechanisms maintain genome stability at human centromeres
Scelfo, A., Angrisani, A., Grillo, M., Barnes, B. M., Muyas, F., Sauer, C. M., Leung, C. W. B., Dumont, M., Grison, M., Mazaud, D., et al. (2024) · Molecular Cell · doi:10.1016/j.molcel.2024.01.018 · Cited by 50
Freedom to err: The expanding cellular functions of translesion DNA polymerases
Paniagua, I., & Jacobs, J. J. L. (2023) · Molecular Cell · doi:10.1016/j.molcel.2023.07.008 · Cited by 50
Targeting evolution to inhibit antibiotic resistance
Merrikh, H., & Kohli, R. M. (2020) · FEBS Journal · doi:10.1111/febs.15370 · Cited by 45
Delivery of Small-Molecule Drugs and Protein Drugs by Injectable Acid-Responsive Self-Assembled COF Hydrogels for Combinatorial Lung Cancer Treatment
Meng, T., Wang, X., Jiang, S., Chen, S., Zhou, S., Zhu, Y., Wu, J., Hu, D., Yan, Y., & Zhang, G. (2023) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.3c10074 · Cited by 42
Cisplatin in the era of PARP inhibitors and immunotherapy
Duan, M., Leng, S., & Mao, P. (2024) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2024.108642 · Cited by 45
Beyond Kinases: Targeting Replication Stress Proteins in Cancer Therapy
Baillie, K. E., & Stirling, P. C. (2020) · Trends in cancer · doi:10.1016/j.trecan.2020.10.010 · Cited by 42
Translesion Synthesis or Repair by Specialized DNA Polymerases Limits Excessive Genomic Instability upon Replication Stress
Maiorano, D., Etri, J. E., Franchet, C., & Hoffmann, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22083924 · Cited by 41
ROS-regulated phosphorylation of ITPKB by CAMK2G drives cisplatin resistance in ovarian cancer
Li, J., Zheng, C., Wang, M., Umano, A. D., Dai, Q., Zhang, C., Huang, H., Yang, Q., Yang, X., Lu, J., et al. (2022) · Oncogene · doi:10.1038/s41388-021-02149-x · Cited by 40
Trans-lesion synthesis and mismatch repair pathway crosstalk defines chemoresistance and hypermutation mechanisms in glioblastoma
Cheng, X., An, J., Lou, J., Gu, Q., Ding, W., Droby, G. N., Wang, Y., Wang, C., Gao, Y., Anand, J. R., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-45979-5 · Cited by 41
RETRACTED: Berberine Maintains the Neutrophil N1 Phenotype to Reverse Cancer Cell Resistance to Doxorubicin
Zhang, S., Zhou, L., Zhang, M., Wang, Y., Wang, M., Du, J., Gu, W., Kui, F., Li, J., Geng, S., et al. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01658 · Cited by 37
Retracted
The Rev1-Polζ translesion synthesis mutasome: Structure, interactions and inhibition
Rizzo, A. A., & Korzhnev, D. M. (2019) · The Enzymes · doi:10.1016/bs.enz.2019.07.001 · Cited by 40
Translesion synthesis inhibitors as a new class of cancer chemotherapeutics
Patel, S. M., Dash, R. C., & Hadden, M. K. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.1850692 · Cited by 39
Progress in Research of Nanotherapeutics for Overcoming Multidrug Resistance in Cancer
Maimaitijiang, A., He, D., Li, D., Li, W., Su, Z., Fan, Z., & Li, J. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25189973 · Cited by 39
Self-citation
Regulation of translesion DNA synthesis in mammalian cells
Ma, X., Tang, T., & Guo, C. (2020) · Environmental and Molecular Mutagenesis · doi:10.1002/em.22359 · Cited by 39
Targeting translesion synthesis (TLS) to expose replication gaps, a unique cancer vulnerability
Nayak, S. U., Calvo, J. A., & Cantor, S. B. (2021) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2021.1864321 · Cited by 37
DNA Damage Tolerance Pathways in Human Cells: A Potential Therapeutic Target
Ler, A. A. L., & Carty, M. P. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.822500 · Cited by 37
Spontaneous mutagenesis in human cells is controlled by REV1-Polymerase ζ and PRIMPOL
Gyüre, Z., Póti, Á., Németh, E., Szikriszt, B., Lózsa, R., Krawczyk, M., Richardson, A. L., & Szüts, D. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112887 · Cited by 33
Rev7 loss alters cisplatin response and increases drug efficacy in chemotherapy-resistant lung cancer
Vassel, F.-M., Bian, K., Walker, G. C., & Hemann, M. T. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2016067117 · Cited by 32
Self-citation
Targeting protein–protein interactions in the DNA damage response pathways for cancer chemotherapy
McPherson, K. S., & Korzhnev, D. M. (2021) · RSC Chemical Biology · doi:10.1039/d1cb00101a · Cited by 35
Translesion DNA synthesis mediates acquired resistance to olaparib plus temozolomide in small cell lung cancer
Stanzione, M., Zhong, J., Wong, E., LaSalle, T. J., Wise, J. F., Simoneau, A., Myers, D. T., Phat, S., Sade-Feldman, M., Lawrence, M. S., et al. (2022) · Science Advances · doi:10.1126/sciadv.abn1229 · Cited by 32
Targeting DNA damage response pathways in tumor drug resistance: Mechanisms, clinical implications, and future directions
Zhu, H., Tian, Y., Chen, H., Qian, Y., Li, J., Niu, D., Zhao, W., Wu, Y., Zhang, X., Tang, T., et al. (2025) · Drug Resistance Updates · doi:10.1016/j.drup.2025.101287 · Cited by 30
Inactivation of REV7 enhances chemosensitivity and overcomes acquired chemoresistance in testicular germ cell tumors
Sakurai, Y., Ichinoe, M., Yoshida, K., Nakazato, Y., Saito, S., Satoh, M., Nakada, N., Sanoyama, I., Umezawa, A., Numata, Y., et al. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.06.001 · Cited by 31
Role of Translesion DNA Synthesis in the Metabolism of Replication-associated Nascent Strand Gaps
Khatib, J. B., Nicolae, C. M., & Moldovan, G. (2023) · Journal of Molecular Biology · doi:10.1016/j.jmb.2023.168275 · Cited by 31
REV7 has a dynamic adaptor region to accommodate small GTPase RAN/Shigella IpaB ligands, and its activity is regulated by the RanGTP/GDP switch
Wang, X., Pernicone, N., Pertz, L., Hua, D., Zhang, T., Listovsky, T., & Xie, W. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.010123 · Cited by 33
Intrinsic adriamycin resistance in p53-mutated breast cancer is related to the miR-30c/FANCF/REV1-mediated DNA damage response
Lin, S., Yu, L., Song, X., Bi, J., Jiang, L., Wang, Y., He, M., Xiao, Q., Sun, M., Olopade, O. I., et al. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1871-z · Cited by 29
The in vivo role of Rev1 in mutagenesis and carcinogenesis
Sasatani, M., Zaharieva, E. K., & Kamiya, K. (2020) · Genes and Environment · doi:10.1186/s41021-020-0148-1 · Cited by 27
Molecular mechanisms of assembly and TRIP13-mediated remodeling of the human Shieldin complex
Xie, W., Wang, S., Wang, J., de la Cruz, M. J., Xu, G., Scaltriti, M., & Patel, D. J. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2024512118 · Cited by 29
Replication Fork Remodeling and Therapy Escape in DNA Damage Response-Deficient Cancers
Liptay, M., Barbosa, J. S., & Rottenberg, S. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00670 · Cited by 30
Structural basis for shieldin complex subunit 3–mediated recruitment of the checkpoint protein REV7 during DNA double-strand break repair
Dai, Y., Zhang, F., Wang, L., Shan, S., Gong, Z., & Zhou, Z. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.011464 · Cited by 28
Drugging evolution of antibiotic resistance at a regulatory network hub
Zhai, Y., Pribis, J. P., Dooling, S. W., Garcı́a-Villada, L., Minnick, P. J., Xia, J., Liu, J., Mei, Q., Fitzgerald, D. M., Herman, C., et al. (2023) · Science Advances · doi:10.1126/sciadv.adg0188 · Cited by 26
(Single-stranded DNA) gaps in understanding BRCAness
Schreuder, A., Wendel, T. J., Dorresteijn, C. G. V., & Noordermeer, S. M. (2024) · Trends in Genetics · doi:10.1016/j.tig.2024.04.013 · Cited by 25
MRN–CtIP, EXO1, and DNA2–WRN/BLM act bidirectionally to process DNA gaps in PARPi-treated cells without strand cleavagePreprint
Seppa, I. M., Ceppi, I., Tennakoon, M., Reginato, G., Jackson, J., Rouault, C. D., Agashe, S., Sviderskiy, V. O., Limbu, M., Lantelme, E., et al. (2025) · Genes & Development · doi:10.1101/gad.352421.124 · Cited by 26
CDK2 regulates collapsed replication fork repair in CCNE1-amplified ovarian cancer cells via homologous recombination
Brown, V. E., Moore, S. L., Chen, M., House, N. C. M., Ramsden, P., Wu, H., Ribich, S. A., Grassian, A. R., & Choi, Y. J. (2023) · NAR Cancer · doi:10.1093/narcan/zcad039 · Cited by 25
Aptamers against cancer drug resistance: Small fighters switching tactics in the face of defeat
Sanati, M., Afshari, A. R., Ahmadi, S. S., Kesharwani, P., & Sahebkar, A. (2023) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2023.166720 · Cited by 27
Targeting Replication Stress Response Pathways to Enhance Genotoxic Chemo- and Radiotherapy
Nickoloff, J. A. (2022) · Molecules · doi:10.3390/molecules27154736 · Cited by 30
REV1 promotes lung tumorigenesis by activating the Rad18/SERTAD2 axis
Chen, Y., Jie, X., Xing, B., Wu, Z., Yang, X., Rao, X., Xu, Y., Zhou, D., Dong, X., Zhang, T., et al. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-04567-5 · Cited by 25
Quaternary structural diversity in eukaryotic DNA polymerases: monomeric to multimeric form
Acharya, N., Khandagale, P., Thakur, S., Sahu, J. K., & Utkalaja, B. G. (2020) · Current Genetics · doi:10.1007/s00294-020-01071-1 · Cited by 25
Centromeric DNA amplification triggered by viral proteins activates nuclear cGAS
Lahaye, X., Van, P. T., Chakraborty, C., Shmakova, A., Cao, N. T. B., Ferran, H., Aït-Mohamed, O., Maurin, M., Waterfall, J. J., Kaufer, B. B., et al. (2025) · Cell · doi:10.1016/j.cell.2025.05.008 · Cited by 24
Mechanisms used by cancer cells to tolerate drug-induced replication stress
Segeren, H. A., & Westendorp, B. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215804 · Cited by 23
Selective Inhibition of DNA Polymerase β by a Covalent Inhibitor
Yuhas, S. C., Laverty, D. J., Lee, H., Majumdar, A. K., & Greenberg, M. M. (2021) · Journal of the American Chemical Society · doi:10.1021/jacs.1c02453 · Cited by 19
Division of labor within the DNA damage tolerance system reveals non-epistatic and clinically actionable targets for precision cancer medicine
Spanjaard, A., Shah, R., de Groot, D., Buoninfante, O. A., Morris, B., Lieftink, C., Pritchard, C. E. J., Zürcher, L. M., Ormel, S., Catsman, J. J. I., et al. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkac545 · Cited by 20
Targeting REV7 effectively reverses 5-FU and oxaliplatin resistance in colorectal cancer
Sun, X., Hou, W., Liu, X., Chai, J., Guo, H., & Yu, J. (2020) · Cancer Cell International · doi:10.1186/s12935-020-01668-z · Cited by 23
Upregulation of REV7 correlates with progression of malignant melanoma
Hoshino, A., Nakayama, C., Jiang, S., Sakurai, Y., Kato, T., Numata, Y., Umezawa, A., Ichinoe, M., & Murakumo, Y. (2021) · Pathology International · doi:10.1111/pin.13174 · Cited by 19
REV1 Inhibition Enhances Radioresistance and Autophagy
Ikeh, K., Lamkin, E. N., Crompton, A., Deutsch, J., Fisher, K., Gray, M., Argyle, D. J., Lim, W. Y., Korzhnev, D. M., Hadden, M. K., et al. (2021) · Cancers · doi:10.3390/cancers13215290 · Cited by 19
Self-citation
Tolerating DNA damage by repriming: Gap filling in the spotlight
Jahjah, T., Singh, J. K., Gottifredi, V., & Quinet, A. (2024) · DNA repair · doi:10.1016/j.dnarep.2024.103758 · Cited by 24
Compound 15c, a Novel Dual Inhibitor of EGFRL858R/T790M and FGFR1, Efficiently Overcomes Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Resistance of Non-Small-Cell Lung Cancers
Chen, G., Bao, Y., Weng, Q., Zhao, Y., Lu, X., Fu, L., Chen, L., Liu, Z., Zhang, X., & Liang, G. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01533 · Cited by 19
Disruption of DNA polymerase ζ engages an innate immune response
Martin, S. K., Tomida, J., & Wood, R. D. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.108775 · Cited by 20
Exploring nondegrading molecular glues for protein–protein interactions
Yu, S., Zhou, L., Yang, J., Zhang, J., & Lu, W. (2025) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2025.07.005 · Cited by 18
Translesion DNA Synthesis and Reinitiation of DNA Synthesis in Chemotherapy Resistance
Shilkin, E. S., Boldinova, E. O., Stolyarenko, A. D., Гончарова, Р. И., Chuprov‐Netochin, R. N., Smal, M. P., & Makarova, А. V. (2020) · Biochemistry (Moscow) · doi:10.1134/s0006297920080039 · Cited by 18
REV1: A novel biomarker and potential therapeutic target for various cancers
Zhu, N., Zhao, Y., Mi, M., Lu, Y., Tan, Y., Fang, X., Weng, S., & Yuan, Y. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.997970 · Cited by 18
Catalytic and noncatalytic functions of DNA polymerase κ in translesion DNA synthesis
Sellés‐Baiget, S., Ambjørn, S. M., Carli, A., Hendriks, I. A., Gallina, I., Davey, N. E., Benedict, B., Zarantonello, A., Gadi, S. A., Meeusen, B., et al. (2024) · Nature Structural & Molecular Biology · doi:10.1038/s41594-024-01395-3 · Cited by 23
Visualizing Rev1 catalyze protein-template DNA synthesis
Weaver, T., Cortez, L. M., Khoang, T. H., Washington, M. T., Agarwal, P. K., & Freudenthal, B. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2010484117 · Cited by 18
Functional screening reveals HORMAD1-driven gene dependencies associated with translesion synthesis and replication stress tolerance
Tarantino, D., Walker, C., Weekes, D. B., Pemberton, H. N., Davidson, K., Torga, G., Frankum, J. R., Mendes‐Pereira, A. M., Prince, C., Ferro, R., et al. (2022) · Oncogene · doi:10.1038/s41388-022-02369-9 · Cited by 16
Nanoparticle BAF312@CaP-NP Overcomes Sphingosine-1-Phosphate Receptor-1-Mediated Chemoresistance Through Inhibiting S1PR1/P-STAT3 Axis in Ovarian Carcinoma
Gong, K., Dong, Y., Wang, L., Duan, Y., Yu, J., Sun, Y., Bai, M., & Duan, Y. (2020) · International Journal of Nanomedicine · doi:10.2147/ijn.s248667 · Cited by 15
Investigating the cellular responses of osteosarcoma to cisplatin by confocal Raman microspectroscopy.
Wang, H., Li, J., Qin, J., Li, J., Chen, Y., Song, D., Zeng, H., & Wang, S. (2021) · Journal of Photochemistry and Photobiology. B: Biology · doi:10.1016/j.jphotobiol.2021.112366 · Cited by 11
REV7 in Cancer Biology and Management
Murakumo, Y., Sakurai, Y., Kato, T., Hashimoto, H., & Ichinoe, M. (2023) · Cancers · doi:10.3390/cancers15061721 · Cited by 14
Polyubiquitinated PCNA triggers SLX4-mediated break-induced replication in alternative lengthening of telomeres (ALT) cancer cells
Kim, S., Park, S. H., Kang, N., Ra, J. S., Myung, K., & Lee, K. (2024) · Nucleic Acids Research · doi:10.1093/nar/gkae785 · Cited by 14
DNA damage response inhibition‐based combination therapies in cancer treatment: Recent advances and future directions
Chen, T., Tongpeng, S., Lu, Z., Topatana, W., Juengpanich, S., Li, S., Hu, J., Cao, J., Lee, C., Tian, Y., et al. (2022) · Aging and Cancer · doi:10.1002/aac2.12047 · Cited by 15
The mutational impact of Illudin S on human cells
Casimir, L., Zimmer, S., Racine-Brassard, F., Jacques, P., & Maréchal, A. (2022) · DNA repair · doi:10.1016/j.dnarep.2022.103433 · Cited by 15
Mechanism of nucleotide discrimination by the translesion synthesis polymerase Rev1
Weaver, T., Click, T. H., Khoang, T. H., Washington, M. T., Agarwal, P. K., & Freudenthal, B. (2022) · Nature Communications · doi:10.1038/s41467-022-30577-0 · Cited by 13
Current state of knowledge of human DNA polymerase eta protein structure and disease-causing mutations
Feltes, B. C., & Menck, C. F. M. (2022) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2022.108436 · Cited by 15
Intrinsic base substitution patterns in diverse species reveal links to cancer and metabolism
Gelova, S. P., Doherty, K. N., Alasmar, S., & Chan, K. (2022) · Genetics · doi:10.1093/genetics/iyac144 · Cited by 12
RAD51 is chromatin enriched and targetable in BRCA1-deficient cells
Peng, M., Lee, S., Nair, H. G., MacGilvary, N. J., Cong, K., Kraemer, M., Li, R., McConnell, J., Baer, C. E., Deng, B., et al. (2025) · Molecular Cell · doi:10.1016/j.molcel.2025.08.017 · Cited by 11
REV1-POL ζ Inhibition and Cancer Therapy
Taniguchi, T. (2019) · Molecular Cell · doi:10.1016/j.molcel.2019.07.012 · Cited by 12
Cryo-EM reveals conformational flexibility in apo DNA polymerase ζ
Truong, C. D., Craig, T. A., Cui, G., Botuyan, M. V., Serkasevich, R. A., Chan, K.-Y., Mer, G., Chiu, P., & Kumar, R. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.100912 · Cited by 13
Protein–Protein Interactions in Translesion Synthesis
Dash, R. C., & Hadden, M. K. (2021) · Molecules · doi:10.3390/molecules26185544 · Cited by 13
Cryo-EM structure of the Rev1–Polζ holocomplex reveals the mechanism of their cooperativity in translesion DNA synthesis
Malik, R., Johnson, R. E., Ubarretxena‐Belandia, I., Prakash, L., Prakash, S., & Aggarwal, A. K. (2024) · Nature Structural & Molecular Biology · doi:10.1038/s41594-024-01302-w · Cited by 12
Increased expression of REV7 in small cell lung carcinomas and its association with tumor cell survival and proliferation
Sanoyama, I., Sakurai, Y., Ichinoe, M., Hoshino, A., Kesen, Y., Kato, T., Numata, Y., Umezawa, A., Jiang, S., & Murakumo, Y. (2020) · Pathology International · doi:10.1111/pin.13040 · Cited by 12
Implications of inhibition of Rev1 interaction with Y family DNA polymerases for cisplatin chemotherapyPreprint
Yoon, J.-H., Johnson, R. E., Prakash, L., & Prakash, S. (2021) · Genes & Development · doi:10.1101/gad.348662.121 · Cited by 15
Regulation of temozolomide resistance via lncRNAs: Clinical and biological properties of lncRNAs in gliomas (Review)
Sui, L., Xie, X., Fu, P., Du, J., & Peng, C. Y. (2022) · International Journal of Oncology · doi:10.3892/ijo.2022.5391 · Cited by 11
Cellular resistance mechanisms in cancer and the new approaches to overcome resistance mechanisms chemotherapy
AlSaihati, H., & Rabaan, A. A. (2023) · Saudi Medical Journal · doi:10.15537/smj.2023.44.4.20220600 · Cited by 11
Disrupting the MAD2L2-Rev1 Complex Enhances Cell Death upon DNA Damage
Pernicone, N., Elias, M., Onn, I., Tobi, D., & Listovsky, T. (2022) · Molecules · doi:10.3390/molecules27030636 · Cited by 11

Authors: Wojtaszek, J. L., Chatterjee, N., Najeeb, J., Ramos, A., Lee, M., Bian, K., Xue, J. Y., Fenton, B. A., Park, H., Li, D., Hemann, M. T., Hong, J., Walker, G. C., & Zhou, P.
Affiliations: Duke Medical Center (US)
Massachusetts Institute of Technology (US)
Koch Institute for Integrative Cancer Research At MIT (US)
Duke University (US)
University of Rhode Island (US)
Corresponding author: Hemann, Michael T.
Hong, Jiyong
Walker, Graham C.
Zhou, Pei
ORCID: Wojtaszek, Jessica L.
Chatterjee, Nimrat
Najeeb, Javaria
Lee, Minhee
Bian, Ke
Xue, Jenny Y.
Fenton, Benjamin A.
Park, Hyeri
Li, Deyu
Hemann, Michael T.
Hong, Jiyong
Walker, Graham C.
Zhou, Pei
Venue: Cell
Publisher: Elsevier BV
Published: 2019-06
Volume: 178
Issue: 1
Pages: 152-159.e11
ISSN: 0092-8674 (ISSN-L)
DOI: 10.1016/j.cell.2019.05.028
PMC: PMC6644000
OpenAlex: W2948035094
Cited by: 194
References: 39
Citations by year: 2026: 22 · 2025: 20 · 2024: 42 · 2023: 23 · 2022: 29 · 2021: 18 · 2020: 32 · 2019: 8
FWCI: 7.19
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 392 d)
Locations: Cell (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc-nd)
OSTI OAI (U.S. Department of Energy Office of Scientific and Technical Information) (submittedVersion)
Funders: Alexander and Margaret Stewart Trust
Duke University
National Cancer Institute
National Institute of Environmental Health Sciences
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
Keywords: Rev1, REV7, small molecule inhibitors, cisplatin, chemoresistance, melanoma, adjuvant chemotherapy, protein dimerization, drug resistance
MeSH terms: Y-Family DNA Polymerases, Animals, Antineoplastic Agents, Cell Survival, Cisplatin, DNA Damage, DNA-Directed DNA Polymerase, Female, Humans, Mice, Nude, Mice, Transgenic, Neoplasms, Nucleotidyltransferases, Quinolines, Transfection, Mutagenesis, Xenograft Model Antitumor Assays, Cell Line, Tumor, Tumor Burden, Mice, Gene Knockdown Techniques, Mad2 Proteins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

A Small Molecule Targeting Mutagenic Translesion Synthesis Improves Chemotherapy

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks